Medtronic Faces Dual Test: Courtroom Challenge and MiniMed Deadline Converge
Published on 10/09/2026 at 19:02 | Editorial boerse-global.de
Medtronic is navigating a pivotal stretch on two fronts this week, with a legal challenge from a smaller rival landing just as the company's long-anticipated MiniMed separation reaches its final hours.
The medical technology giant confirmed that its exchange offer for the MiniMed unit expires at midnight New York time on Friday, unless the company opts to extend the window or call off the transaction altogether. The final exchange ratio has been locked in at the upper bound of 4.5939 MiniMed shares for every accepted Medtronic common share, a ceiling that was set on Wednesday. The offer covers as many as 225,361,295 MiniMed shares.
Medtronic filed a second supplement with the U.S. Securities and Exchange Commission on Thursday to bring its tender terms in line with the now-fixed ratio. The paperwork makes clear that allocations may be scaled back if the offer is oversubscribed — should requests outpace the shares available, distribution will be prorated among participating holders. For the company, the split-off represents a significant milestone in reshaping its business portfolio, giving shareholders the option to convert their holdings directly into stock of the carved-out entity.
Applied Medical Seeks Permanent Injunction
While the MiniMed clock ticks down, Medtronic is absorbing fresh legal pressure in its home market. According to media reports, Applied Medical Resources filed a response in court on October 2 seeking a permanent injunction against the company. The dispute centers on allegations that Medtronic monopolized the market for advanced bipolar energy instruments sold into operating rooms. Applied Medical is pushing for a lasting ban on certain sales practices, accusing the larger rival of abusing its market position. Antitrust cases of this kind can carry strategic risks for entrenched medical device makers.
Should investors sell immediately? Or is it worth buying Medtronic?
Investors took a measured view of the litigation. Medtronic shares were quoted at EUR 77.82 on the day, a modest decline of 0.5%, giving the company a market capitalization of roughly EUR 97.59 billion.
Regulatory Wins Stack Up
Even as the courtroom battle heats up, Medtronic has been racking up regulatory victories across its core franchises. On October 1, the American Medical Association granted Category I CPT codes for the company's Altaviva and Symplicity Spyral systems. The billing designations cover therapies for urge incontinence and hypertension, respectively, and bring clarity to reimbursement for these procedures.
The coding news followed a September 30 announcement detailing progress in cardiac diagnostics and treatment. Medtronic secured both FDA clearance and European CE marking for its Affera Prism-2 mapping software, while the PulseSelect ProxBox adapter with integrated software also received CE certification.
R&D Spending and Analyst View
Alongside the portfolio overhaul, Medtronic continues to direct substantial resources into development. In its fiscal 2026 report, the company disclosed research and development spending of USD 2.9 billion and said its technologies have reached more than 82 million patients worldwide.
Barclays weighed in on the stock with an "Equal Weight" rating and a price target of USD 95. The key question for investors is whether Medtronic can put its legal entanglements to rest quickly and press ahead with rolling out new therapies without disruption.
Ad
Medtronic Stock: New Analysis - 9 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
